Axing Restasis Patents Would Stifle Innovation, PhRMA Warns
By Dani Kass ( January 31, 2018, 8:40 PM EST) -- The Pharmaceutical Research and Manufacturers of America on Wednesday warned the Federal Circuit that allowing a district court to invalidate four patents tied to the dry-eye medication Restasis will block innovation in the pharmaceutical industry, as it undercuts protections tied to drugs being successful and filling a "long-felt need."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.